Market closedNon-fractional

ACADIA Pharmaceuticals/ACAD

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Ticker

ACAD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

610

ACAD Metrics

BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$0.01
EPS
0.40
Beta
-
Dividend rate
$2.6B
0.4
2.043
1.726
10.6
12.853
-0.38%
-0.41%
3.2
5.63
7.39
110.08
56.43%
-98.86%
21.10%
-81.49%

What the Analysts think about ACAD

Analyst Ratings

Majority rating from 19 analysts.
Buy

ACAD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
8.01% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$206M
-10.91%
Net income
$17M
-63.89%
Profit margin
8.01%
-59.50%

ACAD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 113.68%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.01
-$0.40
$0.28
$0.10
-
Expected
-$0.08
-$0.43
$0.30
$0.05
$0.19
Surprise
-112.10%
-6.13%
-7.85%
113.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals (ACAD) has a market cap of $2.6B as of July 04, 2024.

What is the P/E ratio for ACADIA Pharmaceuticals stock?

The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 0 as of July 04, 2024.

Does ACADIA Pharmaceuticals stock pay dividends?

No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next ACADIA Pharmaceuticals dividend payment date?

ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.

What is the beta indicator for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell ACADIA Pharmaceuticals stock

Buy or sell ACADIA Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing